OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2026-03-31-accounts

CHARITY NO: 1203103 The Humane Research Trust CIO Helpiny people, saviil9 artymals IMPACT REPORT 2025/26 ri() Learn more about our work at humaneresearch.org.uk

The Humane Research Trust CIO Helpiny people, saviil9 artymals CONTENTS ri ABOUT About 04 Foreword from the Chair and CEO 05 Strategic Objectives 2023-26 08 OUR IMPACT 2025-26 Our impact 09 Anlmal-free research grant programme 10 Promotlng the eff5cacy of anlmal-free research 25 New grants awarded 10 Engagement events 25 Fellowship award 1S Our work featured in Nature 26 2026 funding round 16 Replacing animals in science 27 Ongoing research 17 Thank yous 28 Grant withdrawal 17 Environmental. social and governance strategy 32 Grants completed 18 Published THRT research 24 Independent scientif ic advisory panel 24

The Humane Research Trust CIO Helpiny people, saviil9 artymals GOVERNANCE AND FINANCIALS Our governance framework 33 Statement of the Trustees. responsibilities 45 Charitable objects 34 Independent auditor's report 46 Future plans 34 Audited accounts 52 Appointment and training of Trustees 35 Risk and incident managemernt 36 Investment powers and objectives 37 Pu blic benefit 37 Grant-making policy 38 Our people 39 Reference and administrative details 40 Fi nancial position 41 Investments 43 Reserves policy 44

The Humane Research Trust CIO Helpiny people, saviil9 artymals ABOUT The Humane Research Trust is dedicated to advancing life-saving medical research without the use of animals. Since 1961, we have funded pioneering scientists developing innovative, human-relevant research methods that are more ethical, more reliable, and better able to predict human disease. According to the UK Government's latest statistics. 2.54 million scientific procedures involving living animals were carried out in Great Britain in 2025. While this represents the lowest total recorded under the Animals (Scientific Procedures) Act 1986. more than 1.3 million procedures were conducted for experimental research, with 95% involving mice, f ish, birds or rats. Over half of these experimental procedures supported basic research. and almost half of all procedures involved the creation and breeding of genetically altered animals for future research, Research on animals in UK labs decreased by 3.80A in 2025 S Million 4 mlmion 3 mlllson 2 mllllon 2007 202S

The Humane Research Trust CIO Helpiny people, saviil9 artymals FOREWORD FROM CHAIR AND CEO We are delighted to present The Humane Research Trust's Impact Report and Financial Statements for the period l April 2025 to 31 March 2026. This has been a year of significant progress for the Trust and for the wider animal-free research sector. ee Demand for our funding reached unprecedented levels, demonstrating both the growing scientific interest in human- relevant research methods and the increasing recognition that animal-free approaches can deliver robust. Innovative solutions to some of the most pressing challenges in medical science. Our 2025 funding round l attracted a record 34 applications with a combined value of £5.8 million. 2025-26 Highlights 34 Following rigorous independent peer review, we were pleased to award four new grants across a diverse range of disciplines, from respiratory infection and cancer immunotherapy to age- related eye disease. Together. these projects have the potential to accelerate scierntific discovery while reducing reliance on animals in research. Appllcatlons recelved New grants awarded £624K Combinèd value Beyond new grant awards. we continued to support 22 active research projects at universities cross the United Kingdom, with more than £2 3 million committed to ongoing research at the end of the reporting period. 23 Active r•s8arch projects supportèd These investments reflect our long-term commitment to nurturing scientific excellence and enabling researchers to develop innovative, reproducible and human-relevant methods that can transform biomedical research.

The Humane Research Trust CIO Helpiny people, saviil9 artymals We were also pleased to strengthen our collaborative approach through a new partnership with the Naturewatch Foundation to support the next Humane Research Trust Fellow. By combining expertise and resources. we can increase our impact and help develop the next generation of scientists dedicated to advancing animal-free research. ee Together, we are helping to build a future in which medical research is more humane, more relevant to human biology, and more effective In delivering benefits for patients. During the year, trustees also reviewed how environmental. social and governance considerations are embedded within the Trust's activities and decision-making As a charity committed to creating positive change, we recognise the importance of operating responsibly and sustainably. ensuring that our values are reflected not only in the research we fund but in the way we conduct our work. None of these achievements would be possible without the generosity of our supporters, the dedication of our researchers. the commitment of our Scientific Advisory Panel, and the contribution of our staff and trustees. We extend our sincere thanks to everyone who shares our vision of a future where advances in medicine are achieved without the use of animals. This year we said goodbye to Bryan Homan. a trustee and chair of the board's science sub-committee. We are immensely grateful for his time and valuable contribution to the science programme, which developed significantly under his guidance. We also said goodbye to Professor Aline Miller, a trustee and member of the board's science sub-committee. We thank Aline for her expertise and for the opportunity she afforded us to host our symposium at University of Manchester.

The Humane Research Trust CIO Helpiny people, saviil9 artymals .As we look ahead. we remain ambitious. In 2026 we will launch a new funding call focused on research into neurological conditions and the microbiome, selected by our supporters. We will continue to expand our grant programme. champion the effectivèness of animal-free methods. and raise awareness of the opportunities these approaches offer for both science and society. Janet Tate-smith Chair of Trustees Dr Alison Glles Chief Executive Officer

The Humane Research Trust CIO Helpiny people, saviil9 artymals STRATEGIC OBJECTIVES 2023-26 The Trust's strategy for 2023-26 sets out three objectives towards achieving its mission: st￿ngthen and expand our animal- free research grant programme. Promote the efflcicy of anlmal-free research Prtynot¢ the Trust's sion and mission to the wbli The strategy is underpinned by activities to ensure the Trust remains a sustainable and resilient organisation with sufficient skills, support, and income to deliver its objectives.

The Humane Research Trust CIO Helpiny people, saviil9 artymals OUR IMPACT 2025-26 This year. your support helped.. Fund innovative animal-free research across respiratory disease, cancer. eye disease and infection Support projects with the potential to replace the use of more than 166,000 mice every year Advance human-relevant technologies including organ-on-chip systems, human tissue models and advanced cell culture platforms Contribute to research published in leading scientif ic journals. including Nature and npj Parkinson's Disease

The Humane Research Trust CIO Helpiny people, saviil9 artymals Objective I: Animal-free research grant programme To accelerate progress towards our mission, we seek to engage with more Institutions, diversify the institutions we fund. and increase the amount of funding awarded. The Trust's funding must be used to replace animals in research, and the priority is the development of novel methods that are reproducible. New grants awarded The 2025 Funding Round I closed on 23 February 2025. A record 34 applications were submitted, with a total value of É5.8m. Following peer review by members of our independent scientific advisory panel. four new grants were awarded in August 2025, with a total commitment of £624.027. Read about the grants 10

The Humane Research Trust CIO Helpiny people, saviil9 artymals Dr Margherita Bertuzzi, University of Manchester Development of a next-generation animal-free microfluidic technology to understand antimicrobial immunity against lethal respiratory pathogens in the lungs. Respiratory infections are the fourth leading cause of death worldwide. Among these, fungal infections pose a growing threat. Inhalation of spores fromAspergillus fumigatus- a major mould pathogen causes over 3 million chronic and invasive d iseases annually, resulting in 1.5 million deaths every year. Dr Bertuzzi's team will develop a microfluidic 'lung-on-a-chip platform a miniature, artificial lung environment that mimics the structure and function of human alveoli. Using this platform. the team will study how the alveolar epithelium recognises and kills Aspergillus fumigatus and how these processes influence immune responses, They will also investigate what goes wrong in Chronic Obstructive Pulmonary Disease, where epithelial dysfunction increases susceptibility to fungal infections. The team estimates their model will immediately replace a minimum of 200 mice yearly and wider use of their model will lead to further replacement of at least 2,000 mice in the next 5 years. 14n Dr Margherita Bertuzzi (Principal Investigator) Keira Gordon (PhD student)

The Humane Research Trust CIO Helpiny people, saviil9 artymals Dr Raymond Allan, De Montfort University Development of a humane respiratory epithelial model for pneumococcal infection Pneumonia remains one of the world's deadliest infectious diseases. claiming millions of lives each year. Among its leading culprits is Streptococcus pneumoniae, a bacterium that resides harmlessly in the upper respiratory tract, but under certain conditions shifts to an invasive state. causing severe infection. Dr Allan's team is developing a novel respiratory epithelial model that supports long- term infection under conditions that mimic the human airway. Using small airway epithelial cells grown at an air-liquid interface, the model will reproduce key features of the respiratory tract. including mucus production and the formation of cilia (hairlike structures that help cells communicate) This novel model will offer an attractive. low-cost alternative that can replace animals (mice, chinchillas, rabbits, rats) that are commonly used for treatment screening, cytotoxicity testing, and exploring the mechanisms of pathogenesis. Dr Raymond Allan (Principal Investigator) Divine Derefaka (PhD student) 12

The Humane Research Trust CIO Helping people, Saving anirnals Dr Nick Peake, Sheff ield Hallam University Repurposing surgical waste tissue to develop humanised models for cancer immunotherapy testing Cbowel cancer) Bowel cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths in the UK. Despite advances in surgery and chemotherapy, up to 50Yo of patients experience disease recurrence. highlighting the urgent need for better therapies. Immunotherapy treatments that retrain the patient's own immune system to attack cancer cells - offers enormous promise. However. only 15-20% of bowel cancer patients respond to current immunotherapies. This low success rate is largely due to the complexity of the tumour microenvironment which blocks immune cells from reaching tumours and allow cancer cells to evade detection. Dr Peake's team is repurposing surgical waste tissue and blood samples from bowel cancer patients to create fully humanised. immunocompetent models that accurately replicate the tumour microenvironment. This means they can observe how a patient's immune system responds to their cancer cells. and how the tissue structure acts as a barrier to cancer immunotherapy. y developing a platform based on human tissue and cells. this project could help to reduce reliance on up to165,000 mice used annually in UK cancer research. The research will start in the next financial period. Dr Nick Peake (Principal Investigator) Dr Rhianna Blyth (Research fellow) 13

The Humane Research Trust CIO Helpiny people, saviil9 artymals Dr Yifan Li. Northumbria University (BIRDIE) Biomimetic In-vitro Research with tuneable Deforming surfaces Induced by Elastomer-hydrogel System (age-related eye disease) Eye diseases such as age-related macular degeneration (AMD) and other retinal disorders affect millions worldwide. AMD is one of the leading causes of vision loss in older adults It gradually destroys the cells that support the retina and disrupts the delicate balance of mechanical and biochemical signals that keep the eye healthy, To develop better therapies, scientists need models that replicate both healthy and diseased states of the human eye. That means mimicking not only the chemical environment but also the physical changes that occur as disease advances. Dr Li's team will build a revolutionary platform that replicates the living retina more closely than ever before. Instead of static surfaces, the system will use soft elastomers and hydrogels engineered to bend, stretch, and wrinkle, just like real eye tissue, This means scientists can study how healthy cells behave and how disease begins under conditions that truly reflect human biology. The research will start in the next funding period. Dr Yifan Li (Principal Investigator) 14

The Humane Research Trust CIO Helpiny people, saviil9 artymals Fellowship award Following the successful completion of a fellowship awarded to Dr Luke Green at University of Sheffield, which finished in July 2025, we opened a grant-funding round to identify a new THRT Fellow. At a glance: Applications opened.. December 2025 Applications opened in autumn 2025 and closed on 21 December 2025. A total of 19 Stage l applications were received, in which applicants were asked to describe their research career to date and their future career aspirations, and to outline their research proposal. 19 Stage 1 applications received New partnership with Naturewatch Foundation The nine applicants whose backgrounds. aspirations and research proposals most closely aligned with the intention of the Fellowship were invited to submit a Stage 2 application. The Stage 2 applications will be peer-reviewed by members of our independent scientific advisory panel and a final decision will be taken in May 2026. We are delighted to partner with Naturewatch Foundation on this award. Naturewatch Foundation has a long-standing campaign to end animal experiments and was looking to fund projects to develop alternative methods to animal testing. They approached The Humane Research Trust to SLJggest a partnership. In recognition of our reputation as an experienced funder of high-quality research. Their funding contribution will support public engagement activities by the Fellow. 15

The Humane Research Trust CIO Helpiny people, saviil9 artymals 2026 Funding round - our next funding priority In 2025. we launched a supporter survey with a list of five disease areas for them to choose from for a disease-focused grant call in 2026. The choice was between autoimmune diseases (joints and muscles).. chronic pain.. neurological conditions and the microbiome,. sepsis., and women's reproductive health. These areas are all underserved by animal-free models and cause significant morbidity. We had a very stron9 response and the disease area with the most votes was neurological conditions and the microbiome. We will launch the grant round in June 2026, inviting applications from UK-based researchers focused on this area. We will run a focused fundraising campaign alongside the grant. Sepsls 16.3% Chronlc paln 24% Autoimmune dlseases (Jolnts and muscles) 18.8% Women's reproductlve health 9.2% Neurological conditions and the microbiome 31.7% 16

The Humane Research Trust CIO Helpiny people, saviil9 artymals Ongoing research During the period, the Trust continued to support 23 F)rojects at the Universities of Birmingham (2 projects). Sheffield. East Anglia (3 projects). Aberdeen, Nottingham, Manchester, Reading, Keele. Bristol. Surrey. Oxford. Edinburgh (2 projects), Liverpool John Moores, University College London (3 projects). Glasgow. Royal Veterinary College, and Nottingham Trent. A list of all active research grants during the period is given in Note 7 to the financial statements. It should be noted that Professor Julie Gough, the principal investigator of a project at University of Manchester. is also a trustee of the Trust. This is recorded as a related party transaction in the notes to the financial statements. As at the end of March 2026, over £2.3m has been committed to ongoing research projects at UK universities, across 22 projects. The Trust has made grant commitments until December 2029. Grant withdrawal We awarded Dr Olivier Cexus at University of Surrey a grant in February 2025.. Deciphering the cause of autoimmune thyroi.d diseases using human Immune thyroid organoids. During the contract finalisation process. Dr Cexus withdrew his application following a decision to relocate his work outside of the UK. He thanked the Trust for the opportunity to apply for funding. 17

The Humane Research Trust CIO Helpiny people, saviil9 artymals Grants completed in the reporting period General grant Project: Creating a Systems-level Model of the Neural Mechanisms Underlying Impaired Impulse Control in Parkinson's Disease Principal investigators: Dr Craig McAllister, Dr Hayley MacDonald (now at Bergen, Norway) Pho student: Aliya Warden University: University of Birmingham Impulse control disorders, such as compulsive gambling and binge eating, affect many eople living with Parkinson's disease. particularly those taking dopamine agonist medication. Despite their serious impact on quality of life. it has not been clear why these behaviours develop or how to Identify those most at risk. We funded a research project at the University of Birmingham to address this gap using entirely animal-free methods. The researchers worked directly with people to understand how changes in brain and muscle activity contribute to impaired impulse control in Parkinson's disease. The project revealed distinct patterns of brain and muscle activity li nked to diff Iculties with impulse control in people with Parkinson's disease. Some of these patterns were associated with more impulsive behaviours in everyday life, and greater disease rogression. This research has laid the groundwork for developing objective, human-relevant markers of impulse control difficulties in Parkinson's disease. In the future, these measures could help identify people at risk of developing Impulse control disorders earlier, enabling closer monitoring and more personalised treatment decisions. 18

The Humane Research Trust CIO Helpiny people, saviil9 artymals By studying impulse control directly in people, the findings are immediately relevant to patients and clinicians and help reduce reliance on animal models in Parkinson's research. Planned next steps will propose non-invasive brain stimulation as a treatment option to improve and/or prevent impulse control problems in Parkinson's patients. One key aim will be to apply a brain stimulation protocol alongside the start of dopamine medication in a group of early patients to counteract any deficits in impulse control from the medication. The PhD student who undertook the research. Aliya Warden. successfully defended her thesis in September 2025. She has since begun a postdoctoral fellowship in the Faculty of Electrical Engineering at the Czech Technical University in Prague, where she is advancing her goal of translating scientific knowledge into improved treatments for people with neurological conditions. She has joined a team specialising in neuromodulation techniques. including deep brain stimulation (DBS), applying her expertise In neural signal analysis In Parkinson's disease to optimise DBS therapy and enhance clinically meaningful outcomes. Her research led to 3 peer-reviewed publications. Aliya Warden (PhD student) and Dr Hayley MacDonald Dr Craig McAllister (Principal Investigators) 19

The Humane Research Trust CIO Helpiny people, saviil9 artymals THRT Les Rhoades memorlal studentshlp Project: The Cellular and Molecular Basis of Neurodevelopmental Disorders Principal investigator: Dr Eunchai Kang PhD student: Do Hyeon Gim Unlverslty: University of Aberdeen The human neocortex is the part of the brain responsible for advanced functions like thinking, memory. language. and decision-making. Understanding how the neocortex forms is essential for revealing the root caLJses of human-specific brain conditions. These include neurodevelopmental disorders such as autism and intellectual disability, as well as psychiatric and degenerative disorders like schizophrenia and Alzheimer's disease Animal models, particularly rodents, have long been used in neurological research. But the developing human cortex contains unique neural stem cells that are absent in other species. Fibroblasts Rwowam I hiPSCS JO +ff•rantt￿n Brarn organoids As a result, animal models are limited in their ability to replicate hu man-specif ic neurolog ical d isorders. Skin biopsy Dr Kang's team addressed this challenge by using human cell culture systems to grow three-dimensional structures that replicate the process of human cortical development in the lab. Their research focus was on the influence of the extracellular matrix (ECM), a network of proteins and molecules that surrounds and supports the brain cells. 20

The Humane Research Trust CIO Helpiny people, saviil9 artymals Do Hyeon Gim, the PhD student. has completed his doctoral thesis and undertook postdoctoral training at the University of Oxford. In spring 2026 he secured a prestigious postdoctoral fellowship at University of California. San Francisco. They Identified that the ECM is unique to each type of brain cell and that It changes significantly as the brain develops Importantly. they identified 139 genes involved in the ECM that have been linked previously to neurodevelopmental disorders. This knowledge provides the opportunity for researchers to focus on how these genes regulate normal development and could inform new strategies for treating neurodevelopmental disorders. The team has secured a further É738K from the Medical Research Council to continue this work, The research has led to a publication in Nature Communications and a second paper currently under revision in Nature Neuroscience, both highly prestigious journals. IA Dr Eunchai Kang, Dr Thomas Hiscock (Principal Investlgators) and Do Hyeon Gim (PhD student) alongside their team 21

The Humane Research Trust CIO Helpiny people, saviil9 artymals THRT Fellowshlp Project tltle: Hijack of the host.. Uncovering how bacteria remodel human cell surface proteins to promote infection Fellow and principal investigator: Dr Luke Green PhD student: Paige Wolverson Unlverslty: University of Sheffield Bacterial diseases are a significant health burden globally and the rising resistance of bacteria to the antibiotics used to treat them is now regarded as a major public health threat. To develop alternative treatment strategies, we must increase our understanding of how bacteria are able to get inside human cells. One disease of interest is bacterial meningitis, where bacteria cross the blood-brain barrier and cause Inflammation In the brain, which can be fatal. Traditionally, bacterial infection studies have relied heavily on animal models. particularly genetically modified mice. Our funding enabled Luke's team to use human cells to recreate the blood-brain barrier in a 3D model in the lab. They used the model to study how the bacteria that cause meningitis interact with proteins on a cell's surface and how this enables them to cross the barrier. H•althy r•ll surlace Bact•ilal attaEhm•nt JlJJ•UI lJ•Jl IIILJStration showing how Neisseria meningitidis sticks to human cells U51ng surface molecules. helping it Cause infection. 22

The Humane Research Trust CIO Helpiny people, saviil9 artymals Their model revealed that the bacteria induce the cell to release pro-inflammatory cytokines that increase the permeability of the barrier. Importantly, they were able to show that a specif ic peptide could signif icantly reduce the bacteria's ability to stick to the cell's surface and trigger inflammation, suggesting the peptide could be used as a therapeutic treatment to reduce Infection. The research led to two peer-reviewed publications. The PhD student, Paige Wolverson. successfully defended her PhD and now has a postdoctoral position at Loughborough University working on the blood-brain barrier during infection. Our award has enabled Luke Green to move from the position of Research Fellow to his current position as a Lecturer at the School of Clinical Dentistry in Sheff ield. L, kli, .7 Dr Luke Green (Principal Investlgator) Paige WolVe￿On (PhD Student) 23

The Humane Research Trust CIO Helpiny people, saviil9 artymals Published THRT research During the reporting period, our funded research featured in the below publications. Thomas Walne, Laura Maple, Nan Li, Isabel Christie, Carl Smythe. Ruth Thompson. A novel role for UPFI in safeguarding DNA replication in S phase and beyond. bioRxiv 2025,05.22.655556 Aliya C. M. Warden, Craig J. McAllister. Damian Cruse. Ben Wright & Hayley J. MacDonald. Muscle bursting and corticomotor excitability mark Impaired impulse control in Parkinson's disease. npj Parkinson's Disease volume 12. Article number.. 11 (2026) Aliya C. N. Warden, Damian Cruse, Craig J. McAllister and Hayley J. MacDonald P-bursting as a sensitive neural marker of inhibitory control In healthy older adults.. a linear mixed- effects modelling and threshold-free cluster approach. Journal of Neuroscience 24 February 2026, e1151252026, tsLLoL&doLLr Gim, D, H., Assir, M. Z. K.. Fowler. P. A. F., Morgan, M., Berg, D., Kang, E. Deciphering Cell- Type and Temporal-specific Matrisome Expression Signatures in Human Cortical Development and Neurodevelopmental Disorders via scRNA-Seq Neta-Analysis. 2025 Published 14 Judith Madden, Peter Penson. Philippa Mccabe. Alessio Gamba. An updated systematic review to determine the chemical space of existing physiologically-based kinetic (PBK) models and to determine most commonly used methods of model evaluation. PROSPERO 2025 CRD420251110775 Independent scientific advisory panel Members of our independent scientific advisory panel peer-review grant applicatior)s and are occasionally involved in other activities of the Trust. We post regularly on Linkedln inviting academics around the world to join the panel In this reporting period we are pleased that the r)umber of panel members has increased from 12 to 54, indicating the growing responsibility academics feel towards the replacement of animals in research. 24

The Humane Research Trust CIO Helpiny people, saviil9 artymals Objective 2: Promoting the efficacy of animal-free research The Trust advances human-relevant science by promoting effective non-animal research methods and supporting the development of new alternatives to animal use in medical research. Engagement events We exhibited at the Tissue and Cell Engineering Society conference hosted by the University of Bristol (18-20 June 2025) and the British Microcirculation & Vascular Biology Society conference hosted by the University of Surrey (July 2025). These events provided valuable opportunities to engage with researchers and promote the Trust's mission and funding programmes. In December 2025, we attended the LUSH annual reception at the House of Commons alongside parliamentarians and NGO representatives. LU$ PRIZE As a rrember of the Alliance for Human-Relevant Science, we participated In a Westminster showcase on 4 November 2025, hosted by Steve Pace MP. We were pleased that our local MP for Che3dle, Tom Morrison, attended in support of the Trust As a member of the Alliance for Humar)-Relevant Science, we participated in a Westminster ghowcase and a Royal Society Science Plus event. A Human Focus for 21st Century Life Sciences The latter attracted 320 delegates from academia, industry. parliament and regulatory bodies, with a special issue of Phi losophical Transactions B now in preparation, exploring key themes from the event. Our CEO Dr Alison Giles with THRfpatron Chris Packham CBE 25

The Humane Research Trust CIO Helpiny people, saviil9 artymals Our work featured in Nature One action arising from the symposium we held in partnership with University of Manchester in September 2024 was to send a joint statement to journal editors. Professor Val Speirs from University of Aberdeen led on this, and two of our trustees, Professor Julie Gough and Professor Aline Miller were part of the drafting group. The final piece was published in Nature. "llo￿1 rn hin rn 5c%t1n8(IK'wndJinic￿Irch Comment Journals, fundersand researchersmust get behind alternativestoanimal testing 26

The Humane Research Trust CIO Helpiny people, saviil9 artymals Replacing animals in science: A strategy to support the development, validation and uptake of alternative methods In November 2025. we cautiously welcomed the Government's "R nim Lod&" The document focuses on the replacement of very specific animal tests like in vivo skin irritation testing. Whilst this is good news, many of these tests could have been outlawed before now. The Strategy also includes new infrastructure commitments. backed by £60 million to promote the development of human-relevant models and support the path to regulatory approval of tests and approaches to replace the use of animals. Sadly, the strategy does not provide any detail on replacing the use of animals in basic research. The Trust will continue to advocate for stronger action to replace animals in medical research. working in partnership with others. Progress More Actlon Needed E60m investment Limited focus on basic research Human-relevant models supported No clear replacement roadmap Improved validation pathways Further advocacy required ee Whilst we welcome the Government's commitment to alternative methods and human-relevant models, stronger action is still needed to replace animals in medical research. 27

The Humane Research Trust CIO Helpiny people, saviil9 artymals Thank yous ee The progress highlighted in these pages reflects the generosity, dedication and belief of our supporters. Their commitment enables vital work that would not otherwise be possible. Thank you for standing with us and helping to drive meaningful change for animals. 1130 2220 £64K Donors Supporters Ralsed Thanks to the unwavering support of our community. this has been a year of significant progress for animals. With the backing of 2,220 supporters and 1,130 donors, we raised £63,911. With this, we have been able to invest in innovative. human-relevant research and accelerate our mission to replace the use of animals in science. The following pages celebrate the remarkable contribution of our supporters and the impact we have achieved together. 28

The Humane Research Trust CIO Helpiny people, saviil9 artymals Public support and fundraising The Trust's income is raised entirely from members of the public. through gifts in wills. donations, fundraising activities, in memoriam donations, and shop sales. We are enormously grateful for the generosity of everyone who has supported the Trust during the period. It is only through their actions that we can continue our work. Thank you to Alexei Gaynanov. who raised over £2,000 including Gift Aid for us running in the London Marathon in April 2025. Thank you to Arrandeep Heer-wilson, who organised a charity dinner and dance which raised £600 for us. Gifts in wills We are hugely grateful to the following people who so generously left us gifts in their wills.. Betty Eattersby, Harold Beeching, Amey Bromley. Prudence Buck, Eileen Calder, Charlotte Clayton. Janet Dale, M Date, S Donnelly. Edna Hames, Janet Harding. Susan Holt, David Mayer. Maria Moore, Eric Palmer Elisabeth and Victor Parker Derek Spraggs, Pauline Sugden, Patricia Stride, Patricia Trow. Elaine Tubby. Alexei Gaynanov. after completing the London Marathon Support through our gift shop We have maintained our mail order catalogue and online gift shop, recognising their importance as tools for promoting the Trust and reaching new audiences. Support from shop customer5 continues to make a valuable contribution to the Trust. As well as generating important income. the shop helps introduce new people to THRT and our work. 29

The Humane Research Trust CIO Helpiny people, saviil9 artymals Volunteers and ambassadors The Humane Research Trust is powered by a remarkable community of supporters who give their time, energy and expertise to help advance animal-free medical rèsearch. From fundraising and public engagement to raising awareness in their local communities, our volunteers and ambassadors play an essential role In helping us reach new audiences and inspire support for our mission. Throughout the year, volunteers assisted with mailings. represented the Trust at community events. and delivered talks to local groups, helping more people learn about the Importance of replacing animals in research with human-relevant methods. Their enthusiasm and commitment continue to strengthen our impact across the UK. We are also grateful to Chris Packham and Megan Mccubbin, whose support has helped raise awareness of the Trust and the growing movement towards animal-free science. During the year, they supported our activities on social media and helped judge our annual wildlife and companion animal calendar competition, bringing the Trust's work to wider audiences. 30

The Humane Research Trust CIO Helpiny people, saviil9 artymals Acknowledgements Our achievements are made possible by the dedication of a small and highly committed team of staff. trustees and members of our Independent Scientific Advisory Panel, Special thanks are given to the Trust's small staff team comprising the Chief Executive Officer, the Trust Secretary, Administrator and Marketing & Communications Manager for their exceptional efforts to ensure a continued high standard of service to grantholders, donors, and supporters. In addition, the trustees thank Tim Askham, the consultant finance officer. for his continued support with the Trust's financial management. We would like to thank all the independent scientific advisory panel members who have provided their invaluable expertise in the assessment of grant applications this year. Their expertise ensures that every grant application is rigorously assessed and that the Trust operates to the highest standards of governance and scientific excellence, We were delighted to win the Best Not-for-profit Organisation award at the 2025 Stockport Business Awards in November. The award recognised our clear mission and purpose, our performance against our aims. and our plans for the future. This recognition reflects the collective impact of our supporters, partners, researchers, volunteers and staff, all working together towards a future where medical discoveries no longer depend on animal experiments. The THR T Team at the Stockport Business Awards 31

The Humane Research Trust CIO Helping people, savin9 artymals ENVIRONMENTAL, SOCIAL AND GOVERNANCE STRATEGY Marketlng Flnance Operatlons

The Humane Research Trust CIO Helpiny people, saviil9 artymals GOVERNANCE AND FINANCIALS Our governance framework The Humane Research Trust CIO is an incorporated registered charity, number 1203103, under a constitution signed by the founding trustees on 17 May 2023. The Trust is governed by a board of trustees. All trustees give the1r time freely and no remuneration is paid to any trustee. The trustees who served during the period are listed on page 40. The board of trustees holds four Board meetings a year to agree the overall strategy, policies, and areas of activity. Trustees make decisions on new grants and keep financial performance, reserves, risk and incident management under review. The board of trustees has powers to delegate some decision-making to sub-committees of the 8oard. During the period, sub-committees operated in the four areas of audit & finance. operations, science, and marketing & fundraising. Each sub-committee has terms of reference that are kept under review. Trustees are required to disclose all relevant interests and register them with the chair of the Board and in accordance with the Trust's policy withdraw from discussions where a conflict of Interest exists. Details of trustees. expenses and related party transactions are stated in the notes to the financial statements. 33

The Humane Research Trust CIO Helpiny people, saviil9 artymals Charitable objects The charitable objects of the Trust are the promotior) and encouragement of medical and scientific research and learning and the dissemination of the results of such research for the benefit of the public and in particular (but without prejudice to the generality of the foregoing) in fields that may lead to the elimination of the use of animals and animal products I n medical and scientific research and in all kinds of testing. The Trust, which relies entirely on public donations and fundraising activities. online shop sales and legacies, ende3vours to raise finance for pioneering projects in the UK that lead to improvements in medical research techniques, the advancement of diagnosis and treatment of human diseases and the development of innovative alternatives to the use of animals and animal-derived products in medical research. Future plans As this reporting period marked the final year of our 2023-26 strategy, the next financial period will see the refresh of our strategy. We expect to continue to focus our resources on funding high-quality research to accelerate the development and use of methods to replace animals in medical research. A key consideration will be how we can best support scientists to develop approaches that can be adopted and validated by others This will help build wider trust in anim81-free science. 34

The Humane Research Trust CIO Helpiny people, saviil9 artymals Appointment of trustees The appointment of trustees is governed by the Trust's Constitution, and the board of trustees is authorised to appoint new trustees to fill vacancies arisirng from retirement, resignation or death of an existing trustee. Trustees serve for a 3-year term and can stand for re-appointment for a second 3-year term. The trustees nominate a chair and deputy chair from amongst their number. To provide the strategic leadership that is necessary for the Trust, the board keeps the skill requirements for the trust body under review. Potential new trustees are identified through open competition, personal recommendation or through knowledge of individuals who respect the ethos of the Trust. Candidates are interviewed by a panel of existing trustees and appointments are made subject to candidates meeting trustee eligibility criteria and the completion of a conflicts of interest declaration. The Constitution provides for a minimum of three trustees and a maximum of eleven trustees, During the period two trustees resigned and two new trustees were recruited who will join the Board in June 2026. The trustees all have a professional background, and two are actively involved in medical research. Trustees may seek independent opinions. as appropriate. from members of the Trust's independent Scientific Advisory Panel or from other specialist advisers from time to time. Training of trustees The induction process for any newly appointed trustee comprises meetings with the chair of trustees to explain the powers and responsibilities of the board and to provide a brief history of the Trust Trustees are given copies of key policy documents, the governing constitution, copy minutes and annual reports and accounts together with other financial information. Additionally. any new trustee is mado. aware of the Charity Commission's guidance". 'The Essential Trustee.. What you need to know.. 35

The Humane Research Trust CIO Helpiny people, saviil9 artymals Risk and incident management The Trust maintains a register of the key risks facing the charity. The risks fall into three categories.. f i nancial, operational. and reputational. Each risk is owned by a Board sub-committee that reviews the risks and the corresponding preventive and mitigating actions on a quarterly basis. The board of trustees review5 the register on an annual basis. Further. an incident log is maintained to keep trustees informed of issues that have arisen across the Charity. how they have been dealt with and whether the relevant policies and procedures were fit for purpose or need revision. 36

The Humane Research Trust CIO Helpiny people, saviil9 artymals Investment powers and objectives The constitution authorises the trustees to make and hold investments, at their discretion, using the general funds of the charity. During the accounting period of this report the portion of the Trust's reserves not expected to be utilised within three years was placed in the ethical Investment fund managed by CCLA. a specialist charity fund manager. The Board reviews the rjerformance of its investments at each meeting and, following an extended period of poor performance of CCLA compared to other funds, investigated alternative fund managers. The fund manager Quilter has been appointed Other reserves remain on deposit with a panel of regulated banking institutions, including with the principal banker, and in CCLA'S Deposit Fund. Public benefit The trustees, having had regard to guidance on public benefit issued by the Charity Commission, confirm that the charitable purposes of the Trust fall within the definitions set out in the Charities Act and, therefore. are for the public benefit. 37

The Humane Research Trust CIO Helpiny people, saviil9 artymals Grant making policy The Trust invites grant applications from UK-based scientists from a diverse range of disciplines. Details of how to apply for grants are published on the charity's website. All applications are assessed and scored by three members of the Trust's independent Scientific Advisory Panel for their scier)tific merit and against the research objectives established by the trustees. A panel meeting is held with all the assessors to review and moderate the scores. In some cases, applicants are Invited to interview or are visited prior to a final decision by the Trust board's science sub-committee on which applications to fund. The Trust currently funds PhD studentships, early career post-doctoral research scientists and fellowships Projects cover a wide range of animal-free techniques and human diseases. A cornerstone of the Trust's philosophy is to encourage scientists to develop innovative alternatives to the use of animals in medical research and to fulfil a key role in nurturing the next generation of medical researchers. The trustees reouire grantees to issue reports at not less than annual intervals to enable them to monitor progress of the projects. On completion a final report Is required that details the research undertaken, key findings, publications and presentations arising, and the next steps for the research. The trustees use the number of academic papers accepted for publication, Independent editorial endorsements and citations of these, together with presentations at scientific conferences. as an indicator of impact. Grant recipients may be asked to produce articles for inclusion in the charity's l iterature and to make presentations at internal conferences and seminars. Communication with grantees is a continual process. 38

The Humane Research Trust CIO Helpiny people, saviil9 artymals Our People Staff Day-to-day operations. grant administration and the management of grant applications were delegated to the Trust's staff team. comprising the CEO. Trust Secretary, Administrator, and Marketing & Communications Manager. The Trust also retained a consultant Finance Officer. Together. they support the charity's governance and delivery of its charitable objectives. The salaries of the Trust's employees are reviewed annually by the Board with reference to average earnings in the charity sector for charities of equivalent size, and to the cost of living Independent sclentlflc advlsory panel Grant applications are peer reviewed by the Trust's independent Scientific Advisory Panel, whose members also support other Trust activities as required The panel includes current and former grant holders. together with scientists recruited through open calls on the Trust's website and social media channels Panel members are not remunerated. The Trust has a conflicts of interest policy in place to maintain the objectivity and fairness of the grant application assessment process. Conflicts of interest among panel members can i nclude direct or Indirect financial ties to the applicant or their Institution, personal or academic relationships with the applicants, or other competing loyalties Volunteers The Trust calls upon a considerable number of volunteers throughout the UK to assist with fundraising activities on behalf of the Charity and to promote its objectives and activities. The Trust has a policy in place for the recruitment and management of its volunteers. In the absence of reliable information, which would impose additional demands upon the volunteers. it is not practicable to give an indicative value of unpaid voluntary assistance. 39

The Humane Research Trust CIO Helpiny people, saviil9 artymals Reference and administrative details in Janet Tate-smith (chair) Trustees: lJu12023 Barry Topham (deputy chairl l Jul 2023 Paul Gold lJul 2023 Bryan Homan lJu12023 12 Mar 2026 Gillian Homan lJul 2023 Prof Julie Gough lJul 2023 Kelly Ryan lJul 2023 Prof Aline M iller 8 Sept 2023 5 Dec 2025 Alan Crozier IHon Treasurer) 8 Sept 2023 Natalie Bennett 114Jun 2024 Sam Worthington 114Jun 2024 Charlty Off Ice: Brook House. 29 Bramhall Lane South. Bramhall, SK7 2DN Audltors: Harold Sharp Limited. 5 Brooklands Place, Brooklands Road, Sale. M33 3SD Bankers: Royal Bank of Scotland. 36 St Andrew Square. Edinburgh. EH2 2YB 40

The Humane Research Trust CIO Helpiny people, saviil9 artymals Financial Position The trustees of The Humane Research Trust CIO F)resent the financial statements of the charity for the 12-month period from l April 2025 to 31 March 2026. The financial statements have been prepared in accordance with the accounting policies set out on page 56 and comply with the charity s constitution and "Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their ccounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland effective l January 2015. For the reporting period. the Board planned to run a £907.660 deficit. At year-end. the Trust recorded a deficit of £1,052,692. The main contributing factor to the larger than forecast deficit was unrealised losses in our invested portfolio. The income of the Trust for the 12-month period ended 31 March 2026 totalled £651,187. Legacy income was £361,408, significantly down on the previous period (£1,585,185), but continues to be the dominant source of income for the Trust. Donations were £63,911 including gift aid. The Trust is grateful to its dedicated supporters for their continuing support. In respect of investment returns in the period. £126,132 was earned from interest on deposited reserves. The Trust's policy is to account for interest only as received. In addition, investment income received from dividends & fixed income yields totalled £77,996. On the other hand, our combined invested reserves experienced unrealised valuation losses of £222,190. Accordingly. this amounted to a combined total negative return of £18,062 over 12 months representing approximately -0.3% p.a. on our average investible reserves. It should be noted that 31 March 2026 was an especially low point for investment returns so far in 2026. 41

The Humane Research Trust CIO Helpiny people, saviil9 artymals Governance and support costs during the 12-month period amounted to £309,443. The Trust's priority is to fund high quality research. and trustees therefore keep operating expenses to a minimum, reflected in a small staff base and focused activities. When setting the annual budget and taking decisions on grants. the Trust aims to keep operating costs (excluding shop stock purchases) to within 33-50% of grant expenditure. In the period the ratio was 26%. A second metric is to endeavour to keep operating costs (excluding shop stock purchases) within 25-33Qh of income (excluding shop sales). During the period the figure was 48°A owing to a combination of lower income from legacies than in recent years and a reduction in returns classed as income as funds were moved from deposit to equities Re-imbursement of expenditure on grant awards made by the Trust amounted to £1,159,797 during the period. This was significantly up on the previous period, reflecting the Trust's increased investment in research over the last two years. The Trust continues to be financially sound with total assets minus commitments standing at £2.7m. This allow5 the Board to continue to pursue leading edge research projects that fit with the Trust's ethos and represent good value for money. 42

The Humane Research Trust CIO Helpiny people, saviil9 artymals Investments The charity held £2,361,234 in the Ethical Investment Fund managed by CCLA, comprising both income and accumulation units. Other reserves (£3m) were substantially held on deposit both with various UK regulated banking institutions. in Rathbones High Liquidity Fund and CCLA'S deposit fund. The CCLA Ethical Investment Fund has underperformed over the past few years, prompting trustees to review alternative funds. Trustees were pleased to identify Quilter Investor's Ethical Investment Fund as a suitable alternative that is high-performing end excludes all animal testing and intensive farming practices. The Trust is trarnsitionirng all its funds from the CCLA Ethical Investment Fund to Quilter Investor's Ethical Investment Fund over the course of the next reporting period. 43

The Humane Research Trust CIO Helpiny people, saviil9 artymals Reserves policy The trustees aim to maintain free reserves in unrestricted funds at a level to ensure that operational and governance costs are covered for the period over which the Trust's grant commitments extend. As stated in note 17 on page 66 of the financial statements. the trustees have agreed to make future grant payments amounting to £2.3m until December 2029. The Trust therefore aims to maintain free reserves to cover the operational and governance costs through to 2029. Operational and governance costs are calculated using current costs for the first two years, tapering down over subsequent years. Legacy Income is the dominant income stream of the Trust, with unpredictability in both timing and amount. Grant commitments are normally for research projects of between two and four years, Consequently, there can be time lags between receipt of income and payment of grants. Therefore. the Trust can. and frequently does, hold reserves greater than the amount needed to meet its operational and governance costs for the duration of the grants awarded. 44

The Humane Research Trust CIO Helpiny people, saviil9 artymals Statement of the Trustees, responsibilities The trustees are responsible for preparing the trustees. annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales. and the provisions of the Trust's constitution, requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Trust and of the incoming resources and application of resources, including the income and expenditure, of the Trust for that period. In preparing these financial statements, the trustees are required to.. select suitable accounting policies and then apply them consistently.. observe the methods and principles in the charities SORP.. make judgements and estimates that are reasonable and prudent., state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements., and prepare the financial statements on the going concern basis unless it is Inappropriate to presume that the charity will continue in business. The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Trust and enable them to ensure that the financial statements comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice appl icable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). They are also responsible for safeguarding the assets of the Trust and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. Approval This report was approved by the trustees on the 11/09/26 and signed on their behalf. Janet Tate-smith Chair of trustees 45 15.10.2026

The Humane Research Trust CIO Helpiny people, saviil9 artymals Independent Auditor's Report to the Members and Trustees of The Humane Research Trust CIO We have audited the financial statements of The Humane Research Trust CIO (the 'charity') for the year ended 31 March 2026 which comprise the Statement of Financial Activities, the Balance Sheet. the Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial F2eporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). In our opinion, the f inancial statements.. give a true and fair view of the state of the charity's affairs as at 31 March 2026, and of its incoming resources and application of resources. for the year then ended, have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice., and have been prepared in accordance with the requirements of Charities Act 2011. Basls for oplnlon We conducted our audit in accordance with International Standards on auditing (UK) (ISAS (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requ Irements that are relevant to our audit of the financial statements In the UK, Including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsi bi l ities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 46

The Humane Research Trust CIO Helpiny people, saviil9 artymals Basls for oplnlon We conducted our audit in accordance with International Standards on auditing (UK) (ISAS (UK)) and applicable law. Our responsibilities under those standards are furthèr descri bed in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requ irements that are relevant to our audit of the f inancial statements in the LJK, includi ng the FRC'S Ethical Standard. and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relation to going concern In auditing the financial statements. we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that. individually or collectively. may cast signif icant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described In the relevant sections of this report. 47

The Humane Research Trust CIO Helpiny people, saviil9 artymals Other information The other information comprises the information included in the annual report. other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information, Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements. we are required to determine whether there is a material misstatement In the financial statements or a material misstatement of the other information. If. based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Matters on whlch we are required to report by exception We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, In our opinion.. the i nformation given in the financial statements is inconsistent in any material respect with the trustees. report., sufficient accounting records have not been kept.. the financial statements are not in agreement with the accounting records and returns. or we have not received all the information and explanations we require for our audit. 48

The Humane Research Trust CIO Helpiny people, saviil9 artymals Responsibilities of trustees As explained more fully in the Trustees, Responsibilities Statement set out on pa e45the trustees are responsible for the preparation of financial statements which give a true and fair view, and for such Internal control as the trustees determine is necessary to enable the preparation of firnancial statements that are free from material misstatement, whether due to fraud or error. In preparing the fir)ancial statements. the trustees are responsible for assessing the charity's abil Ity to continue as a going concern, disclosing, as applicable. matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the company or to cease operations. or have no realistic alternative but to do so. Audltor's responslbilitles for the audlt of the financial statements We have been appointed as auditor under the Charities Act 2011, s. 144 and report In accordance with regulations made under the Act and relevant regulations made or having effect thereunder. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAS (UK) will always detect a material misstatement when it exists. Misstatemernts can arise from fraud or error and are considered material if. individually or in the aggregate, they could reasonably be expected to Influence the economic decisions of users taken on the basis of these f i nancial statements. 49

The Humane Research Trust CIO Helpiny people, saviil9 artymals The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: We obtained an understanding of laws, regulations and guidance that affect the Charity, focusing on those that had a direct effect on the financial statements or that had a fundamental effect on its operations. Key laws, regulations and guidance that we identif led included the Charities Act 2011 and relevant tax legislation. We enquired of the Trustees and reviewed correspondence and Trustee meeting minutes for evidence of non-compliance with relevant laws and regulations, We gair)ed an understanding of the controls that the Trustees have in place to prevent and detect fraud. We enquired of the Trustees about any incidences of fraud that had taken place during the accounting period. The risk of fraud and non-compliance with laws and regulations was discussed within the audit team and tests were planned and performed to address these risks We reviewed financial statements disclosures and supporting documentation to assess compliance with relevant laws and regulations discussed above. We enquired of the Trustees about actual and potential litigation and claims. We performed analytical procedures to identify any unusual or unexpected relationships that might indicate risk of material misstatement due to fraud. In addressing the risk of fraud due to management override of internal controls we tested the appropriateness of journal entries and assessed whether the judgements made in making accounting estimates were indicative of a potential bias. 50

The Humane Research Trust CIO Helpiny people, saviil9 artymals There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions. the less likely it is that we would become aware of non-compliance. Auditing standards also limit the aLJdit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion. A f urther description of our responsibilities for the audit of the f inancial statements is located on the Financial Qeporting Council's website at.. www.frc org uk/auditorsresponsibilities. This description forms part of our auditor's report. Use of our report This report is made solely to the charity's trustees, as a body. in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law. we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Frederick Norman Senior Statutory Auditor for and on behalf of Harold Sharp Limited Chartered Accountants and Statutory Auditor 5 8rooklands Place, Sale M33 SSD Date: 15.10.2026 51

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

STATEMENT OF FINANCIAL ACTIVITIES FOR THE PERIOD 1 APRIL 2025 TO 31 MARCH 2026

Notes
Income & Endowments From
Donations & legacies
2
Other trading activities
3
Investment Income
4
Total
Income
Expenditure On
Raising
Funds
5
Charitable activities
Grants
6
Governance
6
Other
6
Total Expenditure
Net Gains/(Losses) on investments
Net Income/(Expenditure)
Reconciliation of Funds
Total Funds brought forward
Total Funds carried forward
Unrestricted
Fund
Restricted
Fund
Total
Funds
Total
Funds
01.04.25 to
31.03.26
01.04.24to
31.03.25
(Restated)
£
£
£
£
425,319
-
425,319
1,660,035
21,740
-
21,740
21,478
204,128
-
204,128
216,638
651,187
-
651,187
1,898,151
(136,594)
-
(136,594)
(124,437)
(1,236,728)
-
(1,236,728)
(781,306)
(11,977)
-
(11,977)
(15,559)
(96,3
0)
-
(96,390)
(97,240)
(1,481,689)
-
(1,481,689)
(222,190)
-
(222,190)
(87,527)
(1,052,692)
-
(1,052,692)
792,082
6,086,449
-
6,086,449
5,294,367
5,033,757
-
5,033,757
6,086,449

The notes on page 55 to 67 form part of these financial statements.

52

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

BALANCE SHEET 31 MARCH 2026

Notes
Fixed Assets
Tangible Assets
11
Investments
12
Current Assets
Stock
13
Debtors
14
Cash at bank and in hand
Current Asset investments
12
Creditors
Amounts falling due within one year
15
Net Current Assets
Total Assets less Current Liabilities
Net Assets
Funds
Unrestricted Funds
Restricted Funds
Total
Funds
Unrestricted
Fund
Restricted
Fund
£
£
51,122
-
3,087,465


2026
2025
Total
Funds
Total
Funds
£
£
51,122
53,042
3,087,465
2,277,464
3,138,587
-
5,455
-
65,410
-
1,796,783
-
467,044
3,138,587
2,330,506
5,455
7,165
65,410
33,629
1,796,783
3,010,267
467,044
1,033,223
2,334,692
-
(439,522)
-
2,334,692
4,084,284
(439,522)
(328,341)
1,895,170
-
1,895,170
3,775,943
5,033,757
-
5,033,757
6,086,449
5,033,757
6,086,449
5,033,757
-
5,033,757
6,08
,449
-
5,033,757
6,08
,449

The financial statements were approved by the Board of Trustees on 11 September 2026 and were signed on its behalf by:

……………………. Janet Tate-Smith Chair of trustees

……………………. Alan Crozier Honorary Treasurer

Oct 15, 2026

53

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

CASH FLOW STATEMENT FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

Notes
Cash flows from operating activities
Cash generated from operations
1
Net cash provided by operating activities
Cash flows from investing activities
Purchase of tangible fixed assets
Purchase of fixed asset investments
Interest received
Net cash provided by/(used in) investing activities
Change in cash and cash equivalents in the
reporting period
Allocation to current asset investments
Cash and cash equivalents at the beginning of the
reporting period
Cash and cash equivalents at the end of the
reporting period
Period
Period
01.04.25 to
31.03.26
01.04.24 to
31.03.25
£
£
(870,937)
841,411
(870,937)
841,411
(2,666)
(6,475)
(1,034,977)
(200,000)
126,132
176,228
(911,511)
(30,247)
(1,782,448)
811,164
568,964
(1,033,223)
3,010,267
3,232,326
1,796,783
3,010,267

54

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE CASHFLOW STATEMENT FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

1. RECONCILIATION OF NET INCOME/EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation Charges
Losses/(gains) on Fixed Asset Disposals
Losses/(gain) on investments
Interest received
(Increase) in stocks
Decrease/(increase) in debtors
Increase in creditors
Net cash provided by operations
Period
Period
01.04.25 to
31.03.26
01.04.24 to
31.03.25
£
£
(1,052,692)
792,082
4,586
4,931
-
1,715
222,191
87,527
(126,132)
(176,228)
1,710
(2,050)
(31,781)
48,509
111,181
84,925
(870,937)
841,411

2. ANALYSIS OF CHANGES IN NET FUNDS

Net Cash
Cash at bank and in hand
Total
At
01.04.2025
Cash flow
Reallocation
At
31.03.2026
£
£
£
£
3,010,267
(1,782,448)
568,964
1,796,783
3,010,267
(1,782,448)
568,964
1,796,783

55

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

1. ACCOUNTING POLICIES

1.1 Basis of preparation of the financial statements

The accounts (financial statements) have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The accounts (financial statements) have been prepared to give a ‘true and fair’ view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a ‘true and fair view’. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s) and with the exception of investments which are included at market value.

The Charity incorporated as a charitable incorporated organisation on the 1[st] July 2023, with the transfer of activities from the previous unincorporated charity The Humane Research Trust. In line with the requirements of the Charities SORP this formation has been treated as a merger. As a result the asset and liabilities of the previous entity were transferred at book value to the Charity with no adjustments considered necessary. All results in the current period relate solely to the new Charity.

1.2 Going concern

The accounts have been drawn up on a going concern basis. In common with many fund-raising charities, the adoption of the going concern basis is dependent on the company receiving adequate fundraising from voluntary income such as donations and legacies. While the Trustees recognise the uncertainties inherent in predicting the timing and level of future funding from voluntary income that is not yet assured, they believe that adequate funding will be secured from donations and legacies.

1.3 Income

Legacies

Legacies are recognised in the period in which the charity becomes legally entitled to the income, notification has been received and the amount can be quantified with reasonable accuracy. It is categorised as unrestricted or restricted funds dependent upon whether expenditure restrictions by donors are placed on such receipts. Donated investments are introduced at the market value at the date of receipt.

Direct giving, fundraising and gift aid

Cash donations are recognised as they are received along with relevant gift aids amounts if applicable.

1.4 Expenditure

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

56

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

1. ACCOUNTING POLICIES - continued

Raising donations and legacies

These include salaries and directly attributable overheads, plus a proportion of central support costs. Grants

These include amounts paid to grant recipients. Governance related

These are the central running costs of the Charity, including strategic oversight and public accountability.

Other support costs

These are other ancillary costs, such as IT costs, not directly related to the activities of the Charity.

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Grants offered subject to conditions which have not been met are noted as a commitment but not accrued as expenditure.

1.5 Tangible fixed assets

Assets costing more than £500 are capitalised and accounted for at historical cost. Depreciation is provided on all tangible fixed assets for Charity use over their useful economic lives at the following rates:

Freehold property 2% per annum on reducing value Fixtures, fittings and office equipment 20% per annum on reducing value

Freehold property

1.6 Stock

Stocks are valued at the lower of cost and net realisable value.

1.7 Taxation

The charity is exempt from corporation tax on its charitable activities under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects.

1.8 Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objectives of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

1.9 Pension and other post-retirement benefits

The Charity operates a defined contribution pension scheme. Contributions payable to the pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

1.10 Investments

All investments are carried at fair value. Holdings in common investment funds restated at their midmarket price. The statement of financial activities includes the nets gains and losses arising on revaluations and disposals throughout the year. Asset sales and purchases are recognised at the date of trade at cost. Investments are managed using the total investment return methodology.

Interest on deposited monies is recognised only on receipt.

57

THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

2. DONATIONS AND LEGACIES

Donations
Gift Aid
Legacies
3.
OTHER TRADING ACTIVITIES
Shop income
4.
INVESTMENT INCOME
Deposit account interest
Investment income
5.
RAISING FUNDS
Raising donations and legacies
Marketing materials
and distribution
IT Costs
Support Costs
Period
01.04.25 to
31.03.26
£
55,510
8,401
361,408
425,319
Period
01.04.25 to
31.03.26
£
21,740
Period
01.04.25 to
31.03.26
£
126,132
77,996
204,128
Period
01.04.25 to
31.03.26
£
23,850
2,880
98,916
125,646
Period
01.04.24 to
31.03.25
£
69,856
4,994
1,585,185
1,660,035
Period
01.04.24 to
31.03.25
£
21,478
Period
01.04.24 to
31.03.25
£
176,228
40,410
216,638
Period
01.04.24 to
31.03.25
(Restated)
£
,9
1,993
,
108,435

58

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

5. RAISING FUNDS - continued

Other trading activities

ther trading activities
Purchases
Aggregate Amounts
Period
01.04.25 to
31.03.26
£
10,948
Period
01.04.24 to
31.03.25
£
16,002
124,437
136,594

Prior Year Restatement

In 2026 a revised analysis of salaries and other support costs between Grants, Governance, Fund raising activities better aligns with the SORP. 2025's allocation of these costs is restated on same basis. This has no impact on the Net Income or Total Reserves.

6. CHARITABLE ACTIVITIES

Period to 31 March 2026

Grants
Governance related
Other Support
costs
Direct costs
Grant
funding
(note 7)
Support
costs
(note 8)
Totals
£
1,501
1,159,797
75,430
1,236,728
1,323
-
10,654
11,977
-
-
96,390
96,390
2,824
1,159,797
182,474
1,345,095

Period to 31 March 2025 (Restated)

Grants
Governance related
Other Support
costs
Direct costs
Grant
funding
Support
costs
(note 8)
Totals
£
3,
712,254
5,
781,306
-
-
15,559
15,559
-
-
97,240
97,240
3,
712,254
1
8,
7
894,105

59

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

7. GRANTS PAYABLE

The below outlines the grants which have been paid during the year

----- Start of picture text -----
Name and recipient Purpose of grant Amount (£)
institution
W , University of 4,851
East Anglia
Dr Rana, University of East Defining a xeno-free human iPSC-derived 3D biomimetic vessel platform for 4,952
Anglia the elucidation of mechanisms that drive vascular remodelling in pulmonary
arterial hypertension
Dr Schuller, University of Development of a microaerobic human intestinal organoid model to determine
East Anglia the role of the gut microbiome in Crohn’s disease 37,718
Dr Allan, de Montfort Development of a humane respiratory epithelial model for pneumococcal 14,067
University infection
Prof Gough, University of Peptide based 3D in vitro platform for drug & toxicity testing 79,174
Manchester
Prof Madden, Liverpool John In Silico Methods to Assist Development of Physiologically-Based Kinetic 44,989
Moores University Models
Dr Bertuzzi, University of Development of a next-generation animal-free microfluidic technology to 11,985
Manchester understand antimicrobial immunity against lethal respiratory pathogens in the
lungs
Dr MacDonald, University of Creating a Systems-level Model of the Neural Mechanisms Underlying 2,595
Birmingham Impaired Impulse Control in Parkinson’s Disease
Dr Hodges, University of Replacing animal testing with innovative spheroid models: targeted 16,070
Birmingham nanoparticle therapy for head and neck cancer
Dr Boussahel, University of A high throughput human vascularised 3D in-vitro model of adipose tissue to
Bristol replace animal testing in drug development for metabolic dysfunction 28,963
Prof (Assoc) Nateri, Development of 3D colorectal cancer patient-derived mini-ring model for high 62,528
University of Nottingham throughput drug screening targeting the tumour microenvironment
Dr Rocha dos Santos, A high-throughput human muscle model for sarcopenia research 37,413
Nottingham Trent University
Dr Obaidi, Advancing respiratory research with patient-specific data-driven lung models 52,176
University of Reading
Dr Orriss, Royal Veterinary Developing non-animal ex vivo and in vitro models for studying arterial medial 55,808
College calcification
Dr Green, University of Hijack of the host: Uncovering how bacteria remodel human cell surface 14,124
Sheffield proteins to promote infection
Dr Kang, University of Cellular and molecular basis of neurodevelopmental disorders 31,897
Aberdeen
Dr George, Keele University Manipulating ependymona oncogenic response using light-inducible genome 69,173
engineering and stem cells
Dr Selvaraj, University of Mechanisms of neuro-muscular junction degeneration in Motor Neuron 179,944
Edinburgh Disease (MND) using human(e) experimental models
Dr Theil, University of Primary cilia and the control of neuronal network activity in 56,107
Edinburgh neurodevelopmental disorders.
Prof Hosie, University of Establishing a human tonsil organoid system to evaluate immune responses to 45,169
Glasgow vaccination
Prof (Assoc) Campagnolo, A 3D model of heart failure-associated microvascular dysfunction 66,303
University of Surrey
Prof Kalaskar, University Developing and investigating the effectiveness of a fully artificial, animal-free 56,968
College London vascular model to study the molecular factors governing blood vessel integrity
and function in health and disease
Dr Holloway, University of Patient-derived brain vascular networks as a new in vitro model of cerebral 70,945
Oxford small vessel disease: Studying the role of matrix remodelling in COL4A1 and
CARASIL
Prof Velliou, University Developing fully synthetic, animal-free peptide based pancreatic cancer 72,218
College London models: Unravelling the role of cell-matrix-peptide interplay on the disease
progression and drug response
Dr Bestmann, University Understanding the dynamics of cortico-spinal interactions in humans 43,660
College London
Total 1,159,797
----- End of picture text -----

60

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

7. GRANTS PAYABLE - continued

In assessing and considering grant applications, the Trustees encourage and support new medical research which does not include the use of animals, with the objective of advancing the diagnosis and treatment of disease in humans. The charity also encourages scientists to develop innovative alternatives to the use of animals in medical research and testing and fulfils an important role in educating the next generation of researchers.

8. SUPPORT COSTS

Period to 31
March 2026
Raising
Donations
Governance
Grants
Other
Period to 31
March 2025
(Restated)
Raising
Donations
Governance
Grants
Other
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
94,774
-
23,850
2,880
4,142
125,646
-
10,547
-
-
1,430
11,977
60,218
5,100
2,335
6,000
1,867
75,430
51,692
-
-
8,138
36,560
96,390
206,594
15,647
26,185
17,018
43,999
309,443
Staff
Consulting
& prof fees
Advertising
&
Marketing
IT Costs
Other
support
costs
Total
£
£
£
£
£
£
8
,
9
1
,
1,993
1
,43
-
2,08
15,559
5,
7,932
-
5,
7

2,164

-
-
-
-
,
1,474
1
,
4
, 97,240
19 ,
2
,
,
16,43
2
,

9. TRUSTEE REMUNERATION AND BENEFITS

No remuneration was paid to any trustee in the year (2025: None).

10. STAFF COSTS

Wages and Salaries
Social Security Costs
Other Pension Costs
Period
01.04.25 to
31.03.26
£
164,815
10,890
30,889
206,594
Period
01.04.24 to
31.03.25
£
149,653
10,736
30,907
191,296

61

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

10. STAFF COSTS - continued

The average monthly number of employees during the period was as follows:

Period Period
01.04.25 to 01.04.24 to
31.03.26 31.03.25
£ £
Administration 4 4

One employee received emoluments in the band of £60,001 - £70,000 (2025: 1).

11. TANGIBLE FIXED ASSETS

COST
At 1 April 2025
Additions
Disposals
At 31 March 2026
DEPRECIATION
At 1 April 2025
Charge for period
Disposals
At 31 March 2026
NET BOOK VALUE
At 31 March 2026
At 1 April 2025
Freehold
property
£
67,546
-
67,546
31,513
746
-
32,259
35,287
36,033
Office
equipment
£
34,129
2,666
-
36,795
1
,
3,840
-
20,960
15,835
17,009
Total
£
101,675
2,666
-
104,341
48,633
4,586
-
53,219
51,122
53,042

Freehold land and buildings were stated at their original historic cost in the accounts of The Lawson Tait Medical and Scientific Research Trust in May 1988, the date when the property was donated to The Humane Research Trust.

The Trustees are of the opinion that the current market value of the freehold land and building is substantially in excess of its net book value. As the property is used solely for the administration of the Trust and there is currently no intention to see, the Trustees cannot justify the cost of a professional valuation.

62

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

12. INVESTMENTS

MARKET VALUE
At 1 April 2025
New Investments
Revaluations
At 31 March 2026
NET BOOK VALUE
At 31 March 2026
At 31 March 2025
Investments
£
2,277,464
1,034,977
(224,976)
3,087,465
3,087,465
2,277,464

There were no investment assets outside the UK. These investments were held in the below:

CCLA ethical investment fund
Rathbone High Liquidity Fund
Bank Deposits (>3mths)
Comparative figures
CCLA ethical investment fund
Rathbone High Liquidity Fund
Bank Deposits (>3mths)
Valuation at 31.03.26
£
2,361,234
687,231
39,000
3,087,465
Valuation at 31.03.25
£
2,277,464
-
-
2,277,464
Historical Cost at 31.03.26
£
2,450,000
695,977
39,000
3,184,977
Historical Cost at 31.03.25
£
2,150,000
-
-
2,150,000

63

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

12. INVESTMENTS (cont.)

Current asset investments represent balances held with a maturity of 3 months or less. At the year end the current assets investments were made up of:

Valuation at 31.03.26
£
Rathbone High Liquidity Fund
302,444
Bank Deposits (<3mths)
164,600
467,044
Comparative figures
Valuation at 31.03.25
£
Rathbone High Liquidity Fund
-
Bank Deposits (<3mths)
1,033,223
1,033,223
Stock
2026
Shop Stock
5,455
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026
£
Prepayments
12,080
Accrued income
53,330
65,410
Historical Cost at 31.03.26
£
300,562
164,600
465,162
Historical Cost at 31.03.25
£
-
1,033,223
1,033,223
2025
7,165
2025
£
4,747
28,882
33,629

13. Stock

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

64

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Trade Creditors
Social security and other taxes
Grants payable
Pensions payable
Accruals and deferred income
2026
£
11,291
4,569
412,112
2,550
9,000
439,522
2025
£
6,393
3,887
305,765
2,483
9,813
328,341

16. MOVEMENT IN FUNDS

Unrestricted
Funds
General Fund
TOTAL FUNDS
At 01.04.2025
Net
Movement in
funds
Inter-fund
Transfers
At 31.03.2026
6,086,
49
(1,052,692)
5,03
,
57
6,086,
49
(1,052,692)
5,03
,
57
-
-

Net movement in funds, included in the above are as follows:

General Fund
TOTAL FUNDS
MOVEMENT
Incoming
resources
Resources
expended
Gains and
Losses
Movement in
funds
651,187
(1,481,689)
(222,190)
(1,052,692)
651,187
(1,481,689)
(222,190)
(1,052,692)

65

HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

16. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

Unrestricted
Funds
General Fund
Restricted Funds
Property Reserve
TOTAL FUNDS
At 01.04.2024
Net
Movement in
funds
Inter-fund
Transfers
At 31.03.2025
5,294,
67
792,082
-
6,086,
49
-
-
-
-
5,294,367
792,082
-
6,086,449

Net movement in funds, included in the above are as follows:

General Fund
Property Reserve
TOTAL FUNDS
MOVEMENT
Incoming
resources
Resources
expended
Gains and
Losses
Movement in
funds
1,898,151
(1,018,5
2)
(87,527)
792,082
-
-
-
-
1,898,151
(1,018,542)
(87,527)
792,082

17. CONTINGENT LIABILITIES

At 31 March 2026 the Trust had agreed to make future grants of £2,338,596 dependant on certain conditions being met by the claimants.

Grant Commitments

Brought Forward at 01.04.25
New commitments in period
Grants paid and incurred in period (note 7)
Commitments revoked in period
Carried Forward at 31.03.26
£
2,993,396
692,769
(1,159,797)
(187,772)
2,338,596

New commitments in period include requests for top-ups to existing grants approved by the Trust.

18. RELATED PARTY DISCLOSURES

Professor Julie Gough (a trustee) is principal investigator on a grant awarded to University of Manchester and received £79,174 (2025: £72,135) in grant funding in the period. The total value of the grant awarded is £226,008.

66

HUMANE RESEARCH TRUST CIO

(INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026

19. CONTINGENT ASSETS

At 31 March 2026, the Trust had been notified, by executors acting for the estates of 21 deceased supporters of the Trust, of indicative amounts of legacies totalling some £556,650, of which aside from one pecuniary legacies amounting to £1,000 are all residual shares. At 31 March 2026, each estate was at a varying stage of completion and neither the final estate accounts nor schedules of interim distributions had been submitted for approval by the residuary legatees

67